Jennison Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
|
|||||
|
2023
Q4 | $32M | Sell |
|
|||||
|
2023
Q3 | $52.1M | Buy |
|
|||||
|
2023
Q2 | $15.4M | Sell |
|
|||||
|
2023
Q1 | $65.6M | Buy |
|
|||||
|
2022
Q4 | $59.9M | Buy |
|
|||||
|
2022
Q3 | $47.8M | Sell |
|
|||||
|
2022
Q2 | $60.4M | Buy |
|
|||||
|
2022
Q1 | $54.5M | Buy |
|
|||||
|
2021
Q4 | $48.8M | Buy |
|
|||||
|
2021
Q1 | – | Sell |
|
|||||
|
2020
Q4 | $39.8M | Sell |
|
|||||
|
2020
Q3 | $49.7M | Sell |
|
|||||
|
2020
Q2 | $936M | Sell |
|
|||||
|
2020
Q1 | $694M | Buy |
|
|||||
|
2019
Q4 | $595M | Sell |
|
|||||
|
2019
Q3 | $562M | Sell |
|
|||||
|
2019
Q2 | $809M | Sell |
|
|||||
|
2019
Q1 | $1.1B | Buy |
|
|||||
|
2018
Q4 | $988M | Buy |
|
|||||
|
2018
Q3 | $1.05B | Sell |
|
|||||
|
2018
Q2 | $1.09B | Sell |
|
|||||
|
2018
Q1 | $954M | Sell |
|
|||||
|
2017
Q4 | $1.05B | Sell |
|
|||||
|
2017
Q3 | $1.15B | Sell |
|
|||||
|
2017
Q2 | $1.2B | Buy |
|
|||||
|
2017
Q1 | $869M | Buy |
|
|||||
|
2016
Q4 | $767M | Sell |
|
|||||
|
2016
Q3 | $898M | Buy |
|
|||||
|
2016
Q2 | $704M | Buy |
|
|||||
|
2016
Q1 | $722M | Buy |
|
|||||
|
2015
Q4 | $701M | Buy |
|
|||||
|
2015
Q3 | $522M | Sell |
|
|||||
|
2015
Q2 | $752M | Buy |
|
|||||
|
2015
Q1 | $673M | Sell |
|
|||||
|
2014
Q4 | $512M | Sell |
|
|||||
|
2014
Q3 | $430M | Buy |
|
|||||
|
2014
Q2 | $333M | Sell |
|
|||||
|
2014
Q1 | $547M | Sell |
|
|||||
|
2013
Q4 | $660M | Buy |
|
|||||
|
2013
Q3 | $641M | Buy |
|
|||||
|
2013
Q2 | $404M | Buy |
|